Neurogene Inc. (NGNE)
17.40
-0.29 (-1.64%)
At close: Mar 03, 2025, 12:47 PM
No 1D chart data available
| Bid | 17.34 |
| Market Cap | 365.05M |
| Revenue (ttm) | 1.14M |
| Net Income (ttm) | -88.03M |
| EPS (ttm) | -4.09 |
| PE Ratio (ttm) | -4.25 |
| Forward PE | -3.97 |
| Analyst | Buy |
| Ask | 17.44 |
| Volume | 36,720 |
| Avg. Volume (20D) | 247,391 |
| Open | 17.56 |
| Previous Close | 17.69 |
| Day's Range | 17.16 - 17.68 |
| 52-Week Range | 14.42 - 74.49 |
| Beta | 1.01 |
About NGNE
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York....
Industry Biotechnology
Sector Healthcare
IPO Date Mar 7, 2014
Employees 91
Stock Exchange NASDAQ
Ticker Symbol NGNE
Website https://www.neurogene.com
Analyst Forecast
According to 6 analyst ratings, the average rating for NGNE stock is "Buy." The 12-month stock price forecast is $60, which is an increase of 244.83% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
3 months ago
-42.58%
Neurgogene shares are trading lower after the comp...
Unlock content with
Pro Subscription
3 months ago
-44.08%
Neurogene shares are trading lower. The company issued interim efficacy data from its first four low-dose pediatric participants in NGN-401 gene therapy clinical trial for Rett Syndrome.
